MedTrace Logo

Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab

NCT00393107 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2006-10-26

No results posted yet for this study

Summary

Purpose of this study was to assess the safety profile and the anti-lymphoma activity of the FC+R combination.

Conditions

Interventions

DRUG

rituximab

DRUG

rituximab,fludarabine, cyclophosphamide

Sponsors & Collaborators

  • Gruppo Italiano Studio Linfomi

    lead OTHER

Principal Investigators

  • Sacchi Stefano, MD · GISL

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-03-31
Completion
2006-08-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00393107 on ClinicalTrials.gov